Skip to Content
Søk Menu

Uveal melanoma: ESMO 2025 updates in 2 minutes

New data from ESMO 2025 highlight striking results for AnzuCell therapy and novel combination strategies in uveal melanoma. Associate Professor Marco Donia, MD, PhD, University of Copenhagen & Clinician-Scientist at Herlev Hospital, Denmark, presents the most promising studies and future perspectives for systemic treatment.
Marco Donia

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Significant therapeutic advancement for patients with HER2-positive biliary tract cancer

/ Jan Andreasen
BrystkreftESMO25NBCN
Marco Donia

Metastatic melanoma: ESMO 2025 updates in 2 minutes

/ Marco Donia
ESMO25Melanom Play the Video 2:34
Marco Donia

Neoadjuvant melanoma: ESMO 2025 updates in 2 minutes

/ Marco Donia
ESMO25Melanom Play the Video 2:27
Teresa Macarulla

ESMO 2025: HER2-Targeted Therapy Advances in BTC

/ Teresa Macarulla
ESMO25NBCN Play the Video 4:06

ESMO 2025: Nye data styrker potensialet for CDK4/6-hemmere ved tidlig brystkreft – Intervju med overlege Egil Støre Blix

/ Egil Støre Blix / Jan Andreasen
BrystkreftESMO25NBCN

Sustained efficacy and quality of life with darolutamide + ADT in mHSPC patients of all ages

/ Jan Andreasen
ESMO25Prostatakreft

RNA Expression Profiles May Guide Future Targeted Therapy in Urothelial Cancer

/ Jan Andreasen
BlærekreftESMO25
Katharina Leuchte

ESMO 2025: High-Intensity Interval Training Promotes Immune Responses in mNSCLC Patients

/ Katharina Leuchte
ESMO25Lungekreft Play the Video 05:43

Combination Therapy with Enzalutamide and Radium-223 in mCRPC: Insights from the REASSURE Study

/ Igle Jan de Jong / Jan Andreasen
ESMO25
Back to top